Table 1 Patients’ baseline characteristics
Total (N = 102) | |
|---|---|
Patient characteristics | |
Age, years | 76 (67–83) |
Male sex | 58 (56.9) |
Height, cm | 1.58 (1.50–1.65) |
Weight, kg | 54.0 (44.8–63.8) |
Body mass index | 21.7 (19.1–25.1) |
Creatinine clearance, mL/min | 21.31 (12.35–39.85) |
Severe renal dysfunction | 54 (52.9) |
Blood urea nitrogen, mg/dL | 39.0 (27.3–57.8) |
Renal replacement therapy | 55 (53.9) |
Malignancy | 22 (21.6) |
Serum albumin, mg/dL | 2.35 (1.92–2.70) |
C reactive protein, mg/dL | 16.99 (9.32–24.10) |
Illness severity | |
SOFA score | 11 (9–14) |
JAAM-DIC score | 6 (5–7) |
SIRS criteria | 3 (2–4) |
Primary type of Infection | |
Intra-abdominal infection | 25 (24.5) |
Pneumonia | 23 (22.5) |
Urinary tract infection | 17 (16.7) |
Cholangitis/Cholecystitis | 9 (8.8) |
Blood stream infection | 7 (6.9) |
Infectious enteritis | 2 (2.0) |
Necrotizing fasciitis/Gas gangrene | 2 (2.0) |
Osteomyelitis | 2 (2.0) |
Iliopsoas muscle abscess/Retroperitoneal abscess | 2 (2.0) |
Othersa | 4 (3.9) |
Unknown | 9 (8.8) |
Treatment | |
Dose reduction of TM alfa | 30 (29.4) |
Duration of TM alfa administration | 6 (4–6) |
Antibiotics | 102 (100.0) |
Antithrombin III | 78 (76.5) |
Heparin | 3 (2.9) |
Fresh frozen plasma | 29 (28.4) |
Platelet Concentrate | 37 (36.3) |
PMX-DHP | 48 (47.1) |
Clinical outcomes | |
DIC resolution up to day 7 | 55 (53.9) |
All-cause mortality at 30 days | 30 (29.4) |
Bleeding complications | 13 (12.7) |